LAUSR

OBJECTIVES According to the data, approximately 33-37% of women of reproductive age are obese. These numbers are reflected in the increasing number of complications in pregnancy, including gestational diabetes. The study aims to assess the concentrations of adropin in the course of gestational diabetes and their possible relationship with the occurrence of obstetric complications characteristic for it. MATERIAL AND METHODS The study included 65 obese and overweight pregnant patients (BMI > 27 kg/m²) with glycemic disorders diagnosed during pregnancy. Blood samples we collected during visits: V0 - the first half of pregnancy V1 - 28-32 weeks of gestation, and V2 - 37-39 weeks of gestation. The concentrations of adropin were measured during V1 and V2 by ELISA tests. We analyzed the studied patients' anthropometric, metabolic parameters and obstetrical results. RESULTS In the study group, at the visit V1, the mean level of adropin was 525.5 mmol/mL and 588.1 mmol/mL for the V2 visit. The comparison of adropin concentration between visits showed a statistically significant increase (p = 0.02). The concentration of adropin did not differ between obese and morbidly obese patients at V1, but at V2, there was a significant lover adropin level in morbidly obese patients. CONCLUSIONS In overweight and obese pregnant patients with gestational diabetes, the levels of adropin in serum increased significantly in the last trimester of pregnancy. The increase in concentration was significantly lower in the morbidly obese patients than in the obese group. The study provides the basis for further analyses of the role of adropin in pregnancies complicated by obesity and gestational diabetes.